Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × cixutumumab × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Carcinoma, Islet Cell 1 Carcinoma 1 Carcinoid Tumor 1

Interventions

Sunitinib 2 Everolimus 2 repotrectinib 1 pralsetinib 1 pasireotide 1 lutetium Lu 177 dotatate 1 epothilone B 1 cixutumumab 1 avelumab 1 Radiotherapy 1 Octreotide 1 Lutetium-177 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00781911 2019-09-20

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Eli Lilly and Company

Phase 2 Completed

43 enrolled 12 charts

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡